Oncogenic PAX6 elicits CDK4/6 inhibitor resistance by epigenetically inactivating the LATS2‐Hippo signaling pathway

Intrinsic resistance to CDK4/6 inhibitors hinders their clinical utility in cancer treatment. Furthermore, the predictive markers of CDK4/6 inhibitors in gastric cancer (GC) remain incompletely described. Here, we found that PAX6 expression was negatively correlated with the response to palbociclib...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Yi, He, Long‐Jun, Huang, Lin‐Lin, Yao, Sheng, Lin, Nan, Li, Ping, Xu, Hui‐Wen, Wu, Xi‐Wen, Xu, Jian‐Liang, Lu, Yi, Li, Yan‐Jie, Zhu, Sen‐Lin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8382979/
https://www.ncbi.nlm.nih.gov/pubmed/34459131
http://dx.doi.org/10.1002/ctm2.503

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8382979/
https://www.ncbi.nlm.nih.gov/pubmed/34459131
http://dx.doi.org/10.1002/ctm2.503

Ejemplares similares